DK3687513T3 - Behandling af fragilt x-syndrom og autisme med cannabidiol - Google Patents

Behandling af fragilt x-syndrom og autisme med cannabidiol Download PDF

Info

Publication number
DK3687513T3
DK3687513T3 DK18788905.0T DK18788905T DK3687513T3 DK 3687513 T3 DK3687513 T3 DK 3687513T3 DK 18788905 T DK18788905 T DK 18788905T DK 3687513 T3 DK3687513 T3 DK 3687513T3
Authority
DK
Denmark
Prior art keywords
cannabidiol
autism
fragile
syndrome
treatment
Prior art date
Application number
DK18788905.0T
Other languages
English (en)
Inventor
Marcel Bonn-Miller
Donna Gutterman
John Messenheimer
Terri Sebree
Nancy Tich
Original Assignee
Zynerba Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals Inc filed Critical Zynerba Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3687513T3 publication Critical patent/DK3687513T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK18788905.0T 2017-09-28 2018-09-27 Behandling af fragilt x-syndrom og autisme med cannabidiol DK3687513T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762564834P 2017-09-28 2017-09-28
US201862632532P 2018-02-20 2018-02-20
PCT/IB2018/057519 WO2019064234A1 (en) 2017-09-28 2018-09-27 TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL

Publications (1)

Publication Number Publication Date
DK3687513T3 true DK3687513T3 (da) 2022-03-07

Family

ID=63878731

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18788905.0T DK3687513T3 (da) 2017-09-28 2018-09-27 Behandling af fragilt x-syndrom og autisme med cannabidiol

Country Status (21)

Country Link
US (11) US10213390B1 (da)
EP (2) EP3967301B1 (da)
JP (3) JP7210564B2 (da)
KR (2) KR20220045070A (da)
AU (1) AU2018343256A1 (da)
BR (1) BR112020005918A2 (da)
CA (1) CA3077330A1 (da)
CY (1) CY1125071T1 (da)
DK (1) DK3687513T3 (da)
ES (1) ES2907325T3 (da)
HR (1) HRP20220277T1 (da)
HU (1) HUE058102T2 (da)
IL (1) IL273495A (da)
JO (1) JOP20200082A1 (da)
LT (1) LT3687513T (da)
MX (2) MX2020003606A (da)
PL (1) PL3687513T3 (da)
PT (1) PT3687513T (da)
RS (1) RS62969B1 (da)
SI (1) SI3687513T1 (da)
WO (1) WO2019064234A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220277T1 (hr) 2017-09-28 2022-05-13 Zynerba Pharmaceuticals, Inc. Liječenje fragilnog x sindroma i autizma kanabidiolom
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
GB2589306A (en) * 2019-10-25 2021-06-02 Gw Res Ltd Use of cannabidiol preparations in the treatment of fragile X syndrome
KR102398219B1 (ko) 2020-02-07 2022-05-17 주식회사 뉴로벤티 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
AU2021281118A1 (en) * 2020-05-26 2023-01-05 Zynerba Pharmaceuticals, Inc. Treatment of autism spectrum disorder with cannabidiol
EP4171528A1 (en) * 2020-06-29 2023-05-03 Zynerba Pharmaceuticals, Inc. Treatment of fragile x syndrome with cannabidiol
IL303388A (en) * 2020-12-03 2023-08-01 Zynerba Pharmaceuticals Inc Treatment of refractory convulsions
CN118284412A (zh) * 2021-10-22 2024-07-02 Zyne制药公司 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
FI20020333A0 (fi) 2002-02-20 2002-02-20 Tomi Jaervinen Metyloidun syklodekstriinin uudet kompleksit
US20080139472A1 (en) * 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
ES2534900T3 (es) 2007-07-30 2015-04-30 Zynerba Pharmaceuticals, Inc. Profármacos de cannabidiol, composiciones que comprenden los profármacos de cannabidiol y métodos de uso de los mismos
EP2424525A1 (en) 2009-04-28 2012-03-07 AllTranz Inc. Formulations of cannabidiol and methods of using the same
US20110052694A1 (en) 2009-08-31 2011-03-03 Alltranz Inc. Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
CN105209424B (zh) 2013-01-08 2019-12-13 耶路撒冷希伯来大学伊森姆研究发展有限公司 氟化的cbd化合物、组合物和其用途
AU2014340709B2 (en) 2013-10-29 2019-07-04 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
US20160022627A2 (en) 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US20170224634A1 (en) 2014-05-29 2017-08-10 Insys Development Company, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
CN114191420A (zh) 2014-05-29 2022-03-18 雷迪厄斯制药公司 稳定的大麻素类化合物制剂
US20160271252A1 (en) 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
CA2953684C (en) 2014-06-27 2023-01-03 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same
US20160000843A1 (en) 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
CA2965493C (en) 2014-10-21 2021-12-07 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US20190125779A1 (en) 2014-12-30 2019-05-02 University Of Houston System Pharmaceutical compositions
US20160338974A1 (en) 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
CA2978605A1 (en) 2015-03-02 2016-09-09 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
WO2017068349A1 (en) 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
WO2017151980A1 (en) 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
EP3423033A4 (en) 2016-03-04 2020-01-01 Sharon Anavi-Goffer SELF-EMULSIFYING COMPOSITIONS OF CB2 RECEPTOR MODULATORS
CA3017696A1 (en) 2016-03-16 2017-09-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition
GB2549278B (en) 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
GB2549277B (en) 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
EP3445179A4 (en) 2016-04-19 2020-07-22 Canna-B Cure Ltd ENZYMATICALLY TREATED THERAPEUTIC COMPOSITION ENRICHED IN CANNABIS
BR112018075073A2 (pt) 2016-06-02 2019-04-30 Acerus Pharmaceutical Corporation composições nasais de canabidiol
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
HRP20220277T1 (hr) 2017-09-28 2022-05-13 Zynerba Pharmaceuticals, Inc. Liječenje fragilnog x sindroma i autizma kanabidiolom
MX2021007076A (es) 2018-12-14 2021-08-11 Zynerba Pharmaceuticals Inc Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
AU2021281118A1 (en) 2020-05-26 2023-01-05 Zynerba Pharmaceuticals, Inc. Treatment of autism spectrum disorder with cannabidiol
EP4171528A1 (en) 2020-06-29 2023-05-03 Zynerba Pharmaceuticals, Inc. Treatment of fragile x syndrome with cannabidiol

Also Published As

Publication number Publication date
US20230000790A1 (en) 2023-01-05
US20190262280A1 (en) 2019-08-29
US20220096396A1 (en) 2022-03-31
KR20200058513A (ko) 2020-05-27
RS62969B1 (sr) 2022-03-31
ES2907325T3 (es) 2022-04-22
KR20220045070A (ko) 2022-04-12
PL3687513T3 (pl) 2022-04-19
US10213390B1 (en) 2019-02-26
CA3077330A1 (en) 2019-04-04
BR112020005918A2 (pt) 2020-10-06
JP2022064988A (ja) 2022-04-26
EP3687513B1 (en) 2021-12-15
PT3687513T (pt) 2022-03-01
JOP20200082A1 (ar) 2020-04-30
US20200214995A1 (en) 2020-07-09
US10314792B2 (en) 2019-06-11
US11458110B2 (en) 2022-10-04
CY1125071T1 (el) 2023-06-09
US10568848B2 (en) 2020-02-25
JP7210564B2 (ja) 2023-01-23
US11779549B2 (en) 2023-10-10
US20190117588A1 (en) 2019-04-25
IL273495A (en) 2020-05-31
AU2018343256A1 (en) 2020-04-02
EP3967301B1 (en) 2024-06-19
LT3687513T (lt) 2022-03-10
MX2020003606A (es) 2020-10-28
US10758497B2 (en) 2020-09-01
HUE058102T2 (hu) 2022-07-28
US20200030255A1 (en) 2020-01-30
US10471022B2 (en) 2019-11-12
WO2019064234A1 (en) 2019-04-04
HRP20220277T1 (hr) 2022-05-13
MX2022012424A (es) 2022-11-30
US20190167605A1 (en) 2019-06-06
JP2023040166A (ja) 2023-03-22
EP3687513A1 (en) 2020-08-05
SI3687513T1 (sl) 2022-04-29
US20230364028A1 (en) 2023-11-16
US20230414533A1 (en) 2023-12-28
US20200360299A1 (en) 2020-11-19
EP3967301A1 (en) 2022-03-16
JP2020535190A (ja) 2020-12-03

Similar Documents

Publication Publication Date Title
DK3687513T3 (da) Behandling af fragilt x-syndrom og autisme med cannabidiol
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3612675T3 (da) Mikrofibrilleret cellulose med forbedrede egenskaber og fremgangsmåder til fremstilling af samme
DK3291679T3 (da) Ændring af mikrobielle populationer og modificering af mikrobiota
DK3253875T3 (da) Tau-antisense-oligomerer og anvendelser deraf
DK3504210T3 (da) 7-substituerede sulfonimidoylpurinonforbindelser til behandling og forebyggelse af virusinfektion
DK3039146T3 (da) Produkter og fremgangsmåder til behandling af amyotrofisk lateral sklerose
DK3117310T3 (da) Håndtering af behandling associeret med valgte arkitektoniske indretninger
DK3227675T3 (da) Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
DK3641753T3 (da) Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3302549T3 (da) Kombinationsbehandling af et anti-CD20-antistof med en Bcl-2-inhibitor og en MDM2-inhibitor
DK3288553T3 (da) Kombinationer af cannabinoider og n-acylethanolaminer
DK3558280T3 (da) Forebyggelse og behandling af migræne
DK3341001T3 (da) Sammensætning og fremgangsmåde til behandling og profylakse af tarminfektion og -inflammation
DK3375869T3 (da) Mutanter af uspecifik peroxygenase med høj monooxygenaseaktivitet og anvendelser deraf
DK3576738T3 (da) Gaboxadolmonohydrat i behandling af tinnitus
DK3297654T3 (da) Behandling af post-bariatrisk hypoglykæmi med exendin(9-39)
DK3570940T3 (da) Pridopidin til anvendelse i behandling af fragilt x-syndrom
DK3294740T3 (da) Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion
DK3512506T3 (da) Anvendelse af pridopidin til behandling af retts syndrom
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK2961420T3 (da) Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
DK3275453T3 (da) Farmaceutisk sammensætning med silibinin og ve
DK3102218T3 (da) Behandling af topiske og systemiske bakterieinfektioner